|
Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness |
CADTH |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Infliximab was found to be more effective than methotrexate, etanercept, adalimumab, and ustekinumab through meta-analyses and one randomized controlled trial. Limited data on safety found that the use of infliximab was associated with an increased risk of experiencing an adverse event than methotrexate or 50 mg etanercept. Despite having a high efficacy, the recommended dose of 5mg/kg infliximab was found to be less cost effective than methotrexate, 25 mg etanercept, adalimumab, or 90 mg ustekinumab. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Dermatologic Agents; Immunoglobulin G; Methotrexate; Psoriasiss; Receptors, Tumor Necrosis Factor Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca AccessionNumber 32012000695 Date abstract record published 29/09/2012 |
|
|
|